Clinical Studies on Thyroid Dysfunction Caused by Immune Checkpoint Inhibitors in Tumor Patients

Meng LI; Ben NIU; Jin HU; Yanlin MA

doi:10.12259/j.issn.2095-610X.S20240111

Volume 45 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(1): 67-72

Meng LI, Ben NIU, Jin HU, Yanlin MA. Clinical Studies on Thyroid Dysfunction Caused by Immune Checkpoint Inhibitors in Tumor Patients[J]. Journal of Kunming Medical University, 2024, 45(1): 67-72. doi: 10.12259/j.issn.2095-610X.S20240111

Citation:

Meng LI, Ben NIU, Jin HU, Yanlin MA. Clinical Studies on Thyroid Dysfunction Caused by Immune Checkpoint Inhibitors in Tumor Patients[J]. Journal of Kunming Medical University, 2024, 45(1): 67-72. doi: 10.12259/j.issn.2095-610X.S20240111

Citation:

PDF( 612 KB)

Clinical Studies on Thyroid Dysfunction Caused by Immune Checkpoint Inhibitors in Tumor Patients

doi: 10.12259/j.issn.2095-610X.S20240111

Meng LI¹,
Ben NIU^{1
,
,},
Jin HU¹,
Yanlin MA²

1.
Dept. of Geriatrics
2.
Dept. of Pharmacy，The Affiliated Hospital of Kunming University of Science and Technology; The 1st People’s Hospital of Yunnan Province，Kunming Yunnan 650034，China

Received Date: 2023-09-22
Available Online: 2024-01-04
Publish Date: 2024-01-25

Abstract

Abstract

Objective To investigate the clinical characteristics and risk factors of thyroid dysfunction（TD） in malignant tumor patients treated with immune checkpoint inhibitors（ICIs）. Methods A total of 157 cancer patients who were hospitalized and received ICIs treatment in the First People's Hospital of Yunnan Province from January 2019 to June 2022 were collected and divided into the normal thyroid function group and abnormal thyroid function group based on whether TD had occurred. Fifty-eight patients with the normal thyroid function and 58 patients with the abnormal thyroid function were selected, and 58 healthy adults who underwent the physical examination in our hospital were randomly selected as the control group. The baseline data on the gender, age, tumor and ICIs type, history of surgery before medication, history of radiotherapy and chemotherapy, and the related indicators of liver and kidney function, blood lipids, thyroid hormone levels and so on were collected. The relevant indicators of the three groups were statistically analyzed, and the normal thyroid function group and abnormal thyroid function group were compared to evaluate the clinical characteristics and related risk factors of TD caused by ICIs. Results 1. Among 157 patients treated with ICIs, 58 cases（36.9%） had thyroid dysfunction, including 39 cases of hypothyroidism（including subclinical hypothyroidism）, 9 cases of hyperthyroidism（including subclinical hyperthyroidism）, and 10 cases of pure related antibody abnormality. 2. The analysis of the data of the normal thyroid function group, the abnormal thyroid function group and the control group showed that the age, thyroid stimulating hormone（TSH）, and thyroid function of the three groups were significantly different. TSH） baseline level, free triiodothyronine（FT3） baseline level and aspartate transaminase（AST） baseline level were statistically different（P < 0.05）. There were significant differences in TSH baseline and radiotherapy history between the normal thyroid function group and the abnormal thyroid function group（P < 0.05）; Multivariate analysis showed that the radiotherapy history（OR=7.291, 95%CI= 1.579-33.663, P < .05）, baseline TSH level（OR=3.917, 95%CI= 1.697-9.038, P < 0.05） were the independent risk factors for thyroid dysfunction in cancer patients after ICIs treatment. Conclusion Hypothyroidism is the most common type of TD caused by ICIs in cancer patients. The baseline TSH level and the history of radiotherapy are the independent risk factors for thyroid dysfunction.
- Immunocheckpoint inhibitors,
- Thyroid dysfunction,
- Immune-related adverse events,
- Malignant tumor,
- Risk factor

FullText(HTML)

References(17)

References

[1]	De Miguel M,Calvo E. Clinical challenges of immune checkpoint inhibitors[J]. Cancer Cell,2020,38(3):326-333. doi: 10.1016/j.ccell.2020.07.004
[2]	Postow M A,Callahan M K,Wolchok J D. Immune checkpoint blockade in cancer therapy[J]. J Clin Oncol,2015,33(17):1974-1982. doi: 10.1200/JCO.2014.59.4358
[3]	Schneider B J,Naidoo J,Santomasso B D,et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update[J]. J Clin Oncol,2021,39(36):4073-4126.
[4]	侯静文,马晓君. 程序性死亡受体1抑制剂相关甲状腺功能异常的影响因素分析[J]. 肿瘤基础与临床,2021,34(3):257-260. doi: 10.3969/j.issn.1673-5412.2021.03.020
[5]	魏芬芬,相丽,宋耕,等. PD-1单抗引起甲状腺功能异常的发生情况及相关因素研究[J]. 临床肿瘤学杂志,2020,25(10):930-934.
[6]	Ross D S,Burch H B,Cooper D S,et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid:Official Journal of the American Thyroid Association,2016,26(10):1343-1421. doi: 10.1089/thy.2016.0229
[7]	Postow M A,Sidlow R,Hellmann M D. Immune-related adverse events associated with immune checkpoint blockade[J]. The New England Journal of Medicine,2018,378(2):158-168. doi: 10.1056/NEJMra1703481
[8]	Barroso-Sousa R,Barry W T,Garrido-Castro A C,et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis[J]. JAMA Oncology,2018,4(2):173-182. doi: 10.1001/jamaoncol.2017.3064
[9]	Patel N S,Oury A,Daniels G A,et al. Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment[J]. The Oncologist,2018,23(10):1236-1241.
[10]	Percik R,Liel Y,Urban D,et al. Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: Analyses from a large single tertiary cancer center database[J]. Acta Oncologica (Stockholm,Sweden),2021,60(11):1466-1471. doi: 10.1080/0284186X.2021.1958006
[11]	Delivanis D A,Gustafson M P,Bornschlegl S,et al. Pembrolizumab-induced thyroiditis: Comprehensive clinical review and insights into underlying involved mechanisms[J]. The Journal of Clinical Endocrinology and Metabolism,2017,102(8):2770-2780. doi: 10.1210/jc.2017-00448
[12]	Ruggeri R M,Spagnolo C C,Alibrandi A,et al. Predictors of thyroid adverse events during cancer immunotherapy: A real-life experience at a single center[J]. Journal of Endocrinological Investigation,2023,46(11):2399-2409. doi: 10.1007/s40618-023-02096-2
[13]	Okura N,Asano M,Uchino J,et al. Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: A review[J]. Journal of Clinical Medicine,2020,9(7):2033. doi: 10.3390/jcm9072033
[14]	Campredon P,Mouly C,Lusque A,et al. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients[J]. Presse Medicale (Paris,France,1983),2019,48(4):e199-e207.
[15]	Baek H S,Jeong C,Shin K,et al. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients[J]. BMC Endocrine Disorders,2022,22(1):89. doi: 10.1186/s12902-022-01004-8
[16]	Brilli L,Danielli R,Campanile M,et al. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy[J]. Journal of Endocrinological Investigation,2021,44(8):1719-1726. doi: 10.1007/s40618-020-01480-6
[17]	Pollack R M,Kagan M,Lotem M,et al. Baseline TSH level is associated with risk of anti-PD-1-induced thryoid dysfunction[J]. Endocrine Practice:Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,2019,25(8):824-829. doi: 10.4158/EP-2018-0472

Relative Articles(20)

Relative Articles

[1]	Xingzhu LIU, Yanfei YANG, Xing ZHANG, Liping GE, Feng WANG, Yuqin WU. Analysis of Lipid Metabolism Levels and Related Factors in Children with Kawasaki Disease in Different Courses. Journal of Kunming Medical University, 2023, 44(2): 113-119. doi: 10.12259/j.issn.2095-610X.S20230211
[2]	Wenlin ZHOU, Ben NIU, Heng SU. Analysis of Clinical Risk Factors for Idiopathic Hypogonadotropic Hypogonadism. Journal of Kunming Medical University, 2023, 44(7): 64-68. doi: 10.12259/j.issn.2095-610X.S20230727
[3]	Wanyou JIA, Hongli LIU, Weiwei JIANG, Hongmin LI, Shuo ZHANG, Jimin FEI. Risk Factors for Hypoparathyroidism after Thyroidectomy. Journal of Kunming Medical University, 2022, 43(9): 84-89. doi: 10.12259/j.issn.2095-610X.S20220904
[4]	Huajie WU, Nan ZHANG, Lei LI, Han QIAO, Guoping LI. Research Progress in the Risk Factors and Prevention Strategies of Thyroid Cancer. Journal of Kunming Medical University, 2022, 43(5): 162-167. doi: 10.12259/j.issn.2095-610X.S20220526
[5]	Caiying ZHANG, Zhengping KUI, Qiong WANG, Xiaolong ZHAO, Xiaomei HOU, Zhiye QI. Perinatal Risk Factors of Neonatal Hyperthyrotropinemia. Journal of Kunming Medical University, 2022, 43(9): 48-52. doi: 10.12259/j.issn.2095-610X.S20220929
[6]	Jing WANG, Zhenzhen ZHU, Yuxuan BAI, Zhibin JIA, Yanlong REN. Risk Factors of Aspiration Pneumonia Secondary to Swallowing Dysfunction after Stroke. Journal of Kunming Medical University, 2022, 43(2): 141-144. doi: 10.12259/j.issn.2095-610X.S20220214
[7]	Kerong CHEN, Wengang ZHOU, Hongling SHI, Tianyun LIU, Huixian LIN, Mei ZHANG. Risk Factors of Gastroesophageal Reflux in Patients with Swallowing Disorders. Journal of Kunming Medical University, 2022, 43(12): 164-170. doi: 10.12259/j.issn.2095-610X.S20221230
[8]	Zhongting YANG, Xingmei DU, Qingyun YE, Benyan LI, Mingfang QIN, Feng JIAO, Ying CHEN, Rui DENG, Yuan HUANG. Influence of Social Determinants of Health on Overall Survivals among People Died of Cancer. Journal of Kunming Medical University, 2022, 43(7): 97-104. doi: 10.12259/j.issn.2095-610X.S20220727
[9]	Hui DING, Lan YAO. Periodontal Status and Its Influencing Factors in Rural Population aged 65-74 in Yunnan Province. Journal of Kunming Medical University, 2021, 42(4): 38-43. doi: 10.12259/j.issn.2095-610X.S20210407
[10]	Zhu-mei CHEN, Yue-ying HUA, Yan-yan WEN, Hui LI. The Incidence and Influencing Factors of Complications in Patients with Ultrasound-guided PICC Catheterization. Journal of Kunming Medical University, 2021, 42(2): 173-178. doi: 10.12259/j.issn.2095-610X.S20210209
[11]	Ze-zu MENG, Hang XIAN, Xiao-jin HOU, Shi-lei WEI, Ji MA, Rui ZHAO, Rui Cong. Analysis of the Risk Factors Associated with Vascular Crisis after the Digits Replantation. Journal of Kunming Medical University, 2021, 42(1): 130-134. doi: 10.12259/j.issn.2095-610X.S20210122
[12]	Jia LIU, Yin HE, Xin LIU. Risk Factors and Nursing Strategies of PICC Catheter-related Infection in Tumor Patients. Journal of Kunming Medical University, 2021, 42(1): 173-176. doi: 10.12259/j.issn.2095-610X.S20210116
[13]	Li Jun . Analysis of Fatigue and Related Health and Safety Risk Factors Among Taxi Drivers in Kunming. Journal of Kunming Medical University,
[14]	Zhu Zhao . . Journal of Kunming Medical University,
[15]	Jie Yan Hua . . Journal of Kunming Medical University,
[16]	Wang Zhi Min . . Journal of Kunming Medical University,
[17]	Liao Qi Wei . . Journal of Kunming Medical University,
[18]	Li Rui . . Journal of Kunming Medical University,
[19]	Tan Xiang Lai . . Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,